| Cat.No. | Name | Information |
|---|---|---|
| M50211 | AL-002 | AL-002 is a humanized monoclonal antibody targeting myeloid triggered receptor 2 (TREM2) that improves cell survival and proliferation and increases microglia activity by activating TREM2 signaling, and can be used in studies related to Alzheimer's disease (AD). |
| M50201 | BAY-3401016 | BAY-3401016 is a monoclonal antibody targeting SEMA3A for studies related to Alport syndrome. |
| M50200 | BAY-3018250 | BAY-3018250 is a monoclonal antibody targeting α2-antifibrinolytic enzyme (A2AP) for use in studies related to cardiovascular disease. |
| M50198 | Pelgifatamab | Pelgifatamab is a monoclonal antibody targeting prostate cancer-specific membrane antigen (PSMA) for prostate cancer-related studies. |
| M50169 | IPG0521 | IPG0521 is a bifunctional antibody targeting CCR8, which can block CCR8 signaling with high intensity and weak ADCC function, and can effectively inhibit the growth of multiple tumor types in homologous and immunohumanized mouse models. |
| M50168 | IPGA05 | IPGA05 is a monoclonal antibody targeting CCR8 for tumor-related studies. |
| M50167 | PSB-114 | PSB-114 is an ADCC-enhanced targeted CCR8 humanized monoclonal antibody that removes tumor-associated CCR8-expressing Tregs and can be used in tumor-related studies. |
| M50166 | ZL-1218 | ZL-1218 is a novel anti-CCR8 antibody that can be used in studies related to solid tumors. |
| M50165 | HBM1022 | HBM1022 is an anti-CCR8 fully human monoclonal antibody for use in studies related to solid tumors. |
| M50164 | CM369 | CM369 is a potential first-of-its-kind (first-in-class) anti-chemokine receptor 8 (CCR8) monoclonal antibody that binds specifically to CCR8 on Treg and removes immunosuppressive Treg through ADCC action to relieve tumor suppression in the TME.CM369 can be used in studies related to advanced solid tumors. |
| M50163 | BGB-A3055 | BGB-A3055 is a monoclonal antibody targeting CCR8 for studies related to solid tumors. |
| M50162 | AMG-355 | AMG-355 is a monoclonal antibody targeting CCR8 for studies related to solid tumors. |
| M50160 | SRF-114 | SRF-114 is a human IgG1 anti-CCR8 monoclonal antibody that targets tumor Treg cells and induces antibody-dependent cell-mediated cytotoxicity (ADCC) through activation of NK cells, resulting in selective depletion of immunosuppressive tumor T regulatory cells (Tregs) while preserving peripheral Tregs. It can be used for tumor-related studies. |
| M50159 | S-531011 | S-531011 is a novel anti-human IgG1 antibody that exhibits in vitro antibody-dependent cytotoxicity against CCR8-expressing cells and neutralizing activity against the CCL1-CCR8 signaling pathway. It can be used in studies related to solid tumors. |
| M50158 | LM-108 | LM-108 is a novel anti-CCR8 monoclonal antibody that efficiently eliminates tumor-associated Tregs in a mouse model through antibody-dependent cell-mediated cytotoxicity (ADCC) without affecting peripheral Tregs, showing potent anti-tumor activity, and can be used for tumor-related studies. |
| M50155 | DT-7012 | DT-7012 is a potential best-in-class (BIC) monoclonal antibody that effectively depletes the anti-CCR8 receptor of tumor-infiltrating regulatory T cells (Tregs) for use in studies related to cutaneous T-cell lymphoma (CTCL) and solid tumors. |
| M49947 | Ifabotuzumab | Ifabotuzumab is an IgG1κ antibody (KD=610 pM) targeting EphA3. Ifabotuzumab is able to cause apoptosis of tumor cells and activate antibody-dependent cell-mediated cytotoxicity (ADCC), which disrupts the tumor vascular system. In addition, Ifabotuzumab reduces idiopathic pulmonary fibrosis (IPF) CCR10+ cells and ameliorates pulmonary fibrosis. |
| M49822 | ANX005 | ANX005 is a monoclonal antibody that blocks the activation of the entire classical signaling pathway by inhibiting complement protein C1q, which is upstream of the complement cascade reaction, while also maintaining the functional integrity of other complement pathways. It can be used in studies related to Guillain-Barre Syndrome (GBS). |
| M49472 | LY3164530 | LY3164530 is a bispecific antibody targeting c-MET/EGFR that fuses scFv (cetuximab) to the N-terminal end of the heavy chain of emibetuzumab, resulting in a 2+2 symmetric bis-antibody, which is of the IgG4 subtype, and has little to no associated effects such as ADCC. |
| M49470 | MCLA-129 | MCLA-129 is a 1+1 asymmetric c-Met/EGFR bispecific antibody that can be used in a variety of tumor-related studies. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
